Document is current
Any future updates will be listed below
-
Authors
Okar, Serhat V. https://orcid.org/0000-0003-3716-2196
Kawatra, Karan D.
Thommana, Ashley A.
Vultorius, Daniela C.
Nair, Govind
Gaitán, María I.
Norato, Gina
Mina, Yair
Fletcher, Anita
Reich, Daniel S.
Cortese, Irene
-
Funding
Funding for this research was provided by:
National Multiple Sclerosis Society (FG-2208-40289)
The Intramural Research Program of NINDS, NIH (Z01 NS003119)
National Institutes of Health
- License Information
-
More Information
Article History
Received: 16 September 2024
Revised: 10 January 2025
Accepted: 12 January 2025
First Online: 11 February 2025
Declarations
:
: SVO has nothing to disclose. KDK has nothing to disclose. AAT has nothing to disclose. DCV has nothing to disclose.GN has nothing to disclose. MIG has nothing to disclose. GN has nothing to disclose. YM has nothing to disclose. AF has nothing to disclose. DSR has received research funding from Abata and Sanofi, unrelated to the current study. IC is a shareholder of Nouscom AG, Keires AG and PDC*line pharma, unrelated to the current study. The authors have no competing interests related to the content presented in this study.
: The data included in this research was acquired following the approval of the Institutional Review Board and after obtaining written informed consent from the participants, as part of the National Institute of Neurological Disorders and Stroke's “Natural History Study of Progressive Multifocal Leukoencephalopathy” protocol (NCT01730131).
: Participants or their relatives provided consent for publication during the informed consent process within the study protocol. We affirm that the bedside scan photo provided in Fig. does not contain any personally identifiable information, and we have obtained consent from the patient.
